Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759083 | 0.82 | KMT2A (0.69) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL1234089 | 0.81 | KMT2A (0.57) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL23843796 | 0.77 | TSHR (0.61) | KMT2ALMNATP53MAPK1TDP1 | |
| SCHEMBL2759025 | 0.76 | KMT2A (0.62) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL345445 | 0.76 | EGFR (0.49) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL2759053 | 0.74 | LMNA (0.59) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL2759044 | 0.73 | KMT2A (0.48) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL2759039 | 0.73 | KMT2A (0.50) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL16082902 | 0.72 | KMT2A (0.45) | KMT2ALMNATP53SMN1; SMN2ATM | |
| SCHEMBL8725859 | 0.72 | KMT2A (0.38) | KMT2ALMNATP53SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828332-B2 | Non-peptide BDNF neurotrophin mimetics | PharmatorophiX, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828330-B2 | Non-peptide BDNF neurotrophin mimetics | PHARMATROPHIX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828332-B2 | Non-peptide BDNF neurotrophin mimetics | PharmatorophiX, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828330-B2 | Non-peptide BDNF neurotrophin mimetics | PHARMATROPHIX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2011150347-A2 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | KMT2A 3890/4885LMNA 3046/4885TP53 3665/4885 |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | KMT2A 3890/4885LMNA 3046/4885TP53 3665/4885 |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | NTRK2, BDNF, NTRK1 | KMT2A 3852/4885LMNA 2805/4885TP53 3106/4885 |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | KMT2A 3890/4885LMNA 3046/4885TP53 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.